The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG)

被引:35
作者
Betts, David R.
Ammann, Roland A.
Hirt, Andreas
Hengartner, Heinz
Beck-Popovic, Maja
Kuhne, Thomas
Nobile, Luisa
Caflisch, Ueli
Wacker, Pierre
Niggli, Felix K.
机构
[1] Univ Zurich, Childrens Hosp, Dept Oncol, CH-8032 Zurich, Switzerland
[2] Univ Bern, Childrens Hosp, Dept Hematol & Oncol, Bern, Switzerland
[3] Childrens Hosp, Dept Hematol & Oncol, St Gallen, Switzerland
[4] CHU Vaudois, Pediat Hematol Oncol Unit, CH-1011 Lausanne, Switzerland
[5] Univ Basel, Childrens Hosp, Dept Hematol & Oncol, Basel, Switzerland
[6] Childrens Hosp, Dept Oncol, Locarno, Switzerland
[7] Childrens Hosp, Dept Oncol, Luzern, Switzerland
[8] Univ Geneva, Childrens Hosp, Dept Oncol, Geneva, Switzerland
关键词
acute myeloid leukaemia; cytogenetics; child;
D O I
10.1111/j.1600-0609.2007.00854.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In childhood-onset acute myeloid leukaemia (AML) the clinical value of karyotypic aberrations is now acknowledged, although there is still debate concerning the prognostic significance of some events. To add to this knowledge, cytogenetic analysis was performed on a consecutive series of 84 childhood AML patients diagnosed in Switzerland. A result was obtained for all patients, with 69 (82%) showing a clonal karyotypic aberration. In the remaining 15 (18%), no karyotypic aberration was seen by either conventional or fluorescence in situ hybridisation analyses. The most frequent aberrations observed were t(11q23) (19% of all patients), t(8;21) (12%) and +8 (11%). Except for cytogenetics, no clinical parameter was shown to be significantly associated with outcome. The analysis of individual cytogenetic subgroups demonstrated that aberrations involving chromosome 16q were the strongest predictor of a good prognosis, while +8 and complex karyotypes represented the strongest predictors of a poor prognosis. It was also noteworthy that patients with the rare aberrations of del(11q) (n = 4) and t(16;21)(p11;q22) (n = 3) had a poor outcome. The results support the importance of cytogenetic analysis in childhood AML, but show that further work is required in the classification of the poor prognosis aberrations.
引用
收藏
页码:468 / 476
页数:9
相关论文
共 32 条
  • [1] [Anonymous], MODELING SURVIVAL DA
  • [2] Risk assessment in patients with acute myeloid leukemia and a normal karyotype
    Bienz, M
    Ludwig, M
    Mueller, BU
    Leibundgut, EO
    Ratschiller, D
    Solenthaler, M
    Fey, MF
    Pabst, T
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (04) : 1416 - 1424
  • [3] Bloomfield CD, 1997, CANCER-AM CANCER SOC, V80, P2191
  • [4] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
    Byrd, JC
    Mrózek, K
    Dodge, RK
    Carroll, AJ
    Edwards, CG
    Arthur, DC
    Pettenati, MJ
    Patil, SR
    Rao, KW
    Watson, MS
    Koduru, PRK
    Moore, JO
    Stone, RM
    Mayer, RJ
    Feldman, EJ
    Davey, FR
    Schiffer, CA
    Larson, RA
    Bloomfield, CD
    [J]. BLOOD, 2002, 100 (13) : 4325 - 4336
  • [5] Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials
    Creutzig, U
    Zimmermann, M
    Ritter, J
    Reinhardt, D
    Hermann, J
    Henze, G
    Jürgens, H
    Kabisch, H
    Reiter, A
    Riehm, H
    Gadner, H
    Schellong, G
    [J]. LEUKEMIA, 2005, 19 (12) : 2030 - 2042
  • [6] Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission:: the EORTC Children Leukemia Group report
    Entz-Werle, N
    Suciu, S
    ten Bosch, JD
    Vilmer, E
    Bertrand, Y
    Benoit, Y
    Margueritte, G
    Plouvier, E
    Boutard, P
    Vandecruys, E
    Ferster, A
    Lutz, P
    Uyttebroeck, A
    Hoyoux, C
    Thyss, A
    Rialland, X
    Norton, L
    Pages, MP
    Phillippe, N
    Otten, J
    Behar, C
    [J]. LEUKEMIA, 2005, 19 (12) : 2072 - 2081
  • [7] Cytogenetic abnormalities in childhood acute myeloid leukaemia:: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001
    Forestier, E
    Heim, S
    Blennow, E
    Borgström, G
    Holmgren, G
    Heinonen, K
    Johannsson, J
    Kerndrup, G
    Andersen, MK
    Lundin, C
    Nordgren, A
    Rosenquist, R
    Swolin, B
    Johansson, B
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (04) : 566 - 577
  • [8] Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
    Gibson, BES
    Wheatley, K
    Hann, IM
    Stevens, RF
    Webb, D
    Hills, RK
    De Graaf, SSN
    Harrison, CJ
    [J]. LEUKEMIA, 2005, 19 (12) : 2130 - 2138
  • [9] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
    Grimwade, D
    Walker, H
    Oliver, F
    Wheatley, K
    Harrison, C
    Harrison, G
    Rees, J
    Hann, I
    Stevens, R
    Burnett, A
    Goldstone, A
    [J]. BLOOD, 1998, 92 (07) : 2322 - 2333
  • [10] HANN IM, 2004, ANN HEMATOLOGY S1, V83, P108